InvestorsHub Logo
Followers 155
Posts 2622
Boards Moderated 0
Alias Born 01/29/2004

Re: Mikesc post# 413323

Monday, 05/01/2023 3:29:24 PM

Monday, May 01, 2023 3:29:24 PM

Post# of 460333
Better, even, than aspirin.

Didn't TGD refer to 273 as the future aspirin?


Yes, Dr. Missling mentioned that at some time in the future blarcamesine might well be taken daily, much in the manner of aspirin, for prophylactic, disease-preventing purposes.

Today, that conjecture is even more plausible. Specifically, at the time, I believe Missling was alluding to the prevention of Alzheimer's or other CNS neurodegenerative diseases. A perspective similar to those of oncologists; "Find cancers early and treatments can be more effective." In this case, with blarcamesine and Alzheimer's, it is presumed that blarcamesine will, at least, prevent the progression of Alzheimer's symptoms. If started before those symptoms appear, their progression will be obviated and the disease will be absent. The disease is prevented. That's just as good as a "cure." There are increasing numbers of tests that detect yet-asymptomatic cases of ensuing Alzheimer's. These will allow effective prophylactic administration of blarcamesine, to prevent the onset of Alzheimer's.


When that happens, when blarcamesine gains regulatory approval as a CNS disease therapy, it will be incidentally discovered that not only does the drug obviate or reverse the progression of Alzheimer's, Parkinson's, or other diseases approved for blarcamesine, but other good results also occur. One will be the restoration of normalized blood pressure. The drug will also obviate the many problems of insomnia. It's going to be discovered that people taking blarcamesine for any approved CNS disease will concomitantly experience greatly improved general health. Think not? Check the multitude of diseases and conditions noted to be favorably modulated by blarcamesine in Mayo's video posted earlier today.
[See post 413283.]
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News